Exhauvir- Endless antiviral assets

EXHAUVIR is an innovative therapeutic molecule built from two synergistic parts. The first binds with high specificity and affinity to all strains of a virus’s genetic material, triggering natural cellular mechanisms that destroy the virus—without leaving harmful residues. The second acts as a built-in safety and regulation system, minimizing off-target effects that may occur due to the molecule’s high thermal stability, ensuring maximum efficacy with uncompromised safety.

EXHAUVIR offers a unique set of advantages: it is unaffected by viral mutations, can be easily shipped and stored at room temperature, and cannot be translated into proteins. Our molecule binds with exceptionally high affinity compared to RNA or DNA oligos, ensuring robust antiviral activity. With our platform, the molecule can be rapidly adapted to any existing virus or newly emerging viral threat. In-vitro studies across different cell types demonstrated 97.1% protection from virus-induced death. To date, we have developed therapeutic molecules targeting viral respiratory diseases, multiple herpes strains, and measles. Antiviral therapies also reduce long-term risks such as virus-driven cancers or future damages. While our immediate focus is antiviral, the same platform has the potential to expand into oncology and rare genetic disorder- applications already secured within our IP portfolio.